For research use only. Not for therapeutic Use.
KY-02327 acetate, a metabolically stabilized KY-02061 analog, is a potent Dishevelled (Dvl)-CXXC5 interaction inhibitor. KY-02327 acetate shows an activating effect on the Wnt/β-catenin pathway, resulting in promotion of osteoblast differentiation[1].
KY-02327 (1-10 μM; 2 days; MC3T3E1 cells, a murine pre-osteoblast cell line) acetate increases β-catenin protein level together with Runx2 and accumulated nuclear β-catenin in a dose-dependent manner[1].
KY-02327 (1-10 μM) acetate increases the mRNA levels of osteoblast differentiation markers collagen 1a (Col1a) and osteocalcin (OCN)[1].
KY-02327 (20 mg/kg; p.o.; 5 sequential days per week for 4 weeks) acetate successfully rescues bone loss in the ovariectomized (OVX) mouse model[1].
| Catalog Number | I044372 |
| CAS Number | 2989396-34-9 |
| Synonyms | acetic acid;ethyl 5-hydroxy-1-[2-oxo-2-(2-piperidin-1-ylethylamino)ethyl]indole-2-carboxylate |
| Molecular Formula | C22H31N3O6 |
| Purity | ≥95% |
| InChI | InChI=1S/C20H27N3O4.C2H4O2/c1-2-27-20(26)18-13-15-12-16(24)6-7-17(15)23(18)14-19(25)21-8-11-22-9-4-3-5-10-22;1-2(3)4/h6-7,12-13,24H,2-5,8-11,14H2,1H3,(H,21,25);1H3,(H,3,4) |
| InChIKey | YLUUQPHYDMHSNT-UHFFFAOYSA-N |
| SMILES | CCOC(=O)C1=CC2=C(N1CC(=O)NCCN3CCCCC3)C=CC(=C2)O.CC(=O)O |
| Reference | [1]. Kim HY, et al. Small molecule inhibitors of the Dishevelled-CXXC5 interaction are new drug candidates for bone anabolic osteoporosis therapy. EMBO Mol Med. 2016;8(4):375-387. |
